Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms

Graphical abstract

Highlights

- SARS-CoV-2 spike evolves during persistent infection to resist common antibodies
- Antibody affinity maturation is critical to neutralization breadth
- Intra-host evolution foreshadows mutations in circulating spike variants

Authors

Sarah A. Clark, Lars E. Clark, Junhua Pan, ..., Jonathan Z. Li, Anthony Griffiths, Jonathan Abraham

Correspondence

jonathan_abraham@hms.harvard.edu

In brief

Structural and functional analysis of the evolution of SARS-CoV-2 in a persistently infected immunocompromised individual yields insights into mutations that foreshadow emerging viral variants worldwide.
Many individuals mount nearly identical antibody responses to SARS-CoV-2. To gain insight into how the viral spike (S) protein receptor-binding domain (RBD) might evolve in response to common antibody responses, we studied mutations occurring during virus evolution in a persistently infected immunocompromised individual. We use antibody Fab/RBD structures to predict, and pseudotypes to confirm, that mutations found in late-stage evolved S variants confer resistance to a common class of SARS-CoV-2 neutralizing antibodies we isolated from a healthy COVID-19 convalescent donor. Resistance extends to the polyclonal serum immunoglobulins of four out of four healthy convalescent donors we tested and to monoclonal antibodies in clinical use. We further show that affinity maturation is unimportant for wild-type virus neutralization but is critical to neutralization breadth. Because the mutations we studied foreshadowed emerging variants that are now circulating across the globe, our results have implications to the long-term efficacy of S-directed countermeasures.

INTRODUCTION

SARS-CoV-2 has infected over 110 million individuals worldwide, resulting in over 2.4 million deaths to date. The SARS-CoV-2 spike protein (S) is a central target for vaccine and drug design efforts (Abraham, 2020; Krammer, 2020). S is heavily glycosylated and forms trimers of heterodimers on the virion surface. Each S protomer has two functional subunits; S1, which contains a receptor-binding domain (RBD) that binds the cellular receptor, ACE2 (Hoffmann et al., 2020; Zhou et al., 2020), and S2, which mediates fusion of the viral and host cell membranes during viral entry. Epitopes for neutralizing antibodies include non-overlapping sites on the RBD and the S1 N-terminal domain (NTD) (Chi et al., 2020; Du et al., 2020; Hansen et al., 2020; Liu et al., 2020; Robbiani et al., 2020; Wu et al., 2020). V\text{H}3-53 and V\text{H}3-66 antibody genes are identical except for a single amino acid change in an antibody framework region (FWR) (Lefranc and Lefranc, 2001), and potent neutralizing antibodies derived from these germline genes have been isolated from multiple COVID-19 convalescent individuals (Du et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Seydoux et al., 2020; Shi et al., 2020; Wu et al., 2020; Yuan et al., 2020a). All engage the RBD and interfere with viral entry by blocking ACE2 engagement. Coronaviruses encode a viral exonuclease that increases replication fidelity (Denison et al., 2011), which probably makes antigenic drift in SARS-CoV-2 less significant than in other enveloped RNA viruses. Changes in SARS-CoV-2 S have nonetheless occurred over time and become fixed among circulating variants; the D614G S mutation is a prime example (Yurkovetskiy et al., 2020). This mutation, however, does not seem to impact the activity of RBD-targeting neutralizing antibodies (Yurkovetskiy et al., 2020). Ultimately, evolution of S antibody escape mutations could impact the long-term effectiveness of vaccines and monoclonal antibody-based therapeutics that target S.

In our efforts to study SARS-CoV-2 antibody neutralization and to predict escape mutations, we examined sequences of S variants that evolved in a persistently infected individual receiving B cell depleting therapy (Choi et al., 2020). We show that mutations acquired in S during persistent infection confer pseudotype resistance to a large panel of clonally related V\text{H}3-53-derived neutralizing antibodies we isolated from a healthy
Figure 1. Affinity maturation of C1A-VH3-53 antibodies

(A and B) Alignment of antibody variable heavy (A) or light chain (B) gene sequences. The Kabat numbering scheme is used. The C1A-gl sequences shown are germline revertant sequences designed using IMGT/V-QUEST (Brochet et al., 2008). Note in (A) that CDR H3 germline sequences are impossible to predict but we could identify a possible substitution (see Figure 2A). Panels were generated using ESPript3 (Robert and Gouet, 2014) and modified. RBD contacting residues are indicated with a filled black circle.

(C) Ribbon diagram of the crystal structure of the C1A-B3 Fab/RBD complex showing the location of somatic mutations. See also Figure S4.

(D) Interactions for CDR H1 residue 31 with the RBD are shown for C1A-B3 (left panel) or C1A-C2 (right panel) showing the effects of the S31N VH substitution.

(E) Interactions occurring at the base of CDR H1 near the framework regions are shown for C1A-B3 (left panel) or C1A-C2 (right panel) showing the effects of the A24V VH mutation.
COVID-19 convalescent donor. Resistance also extended to B38 (Wu et al., 2020) and CC12.1 (Rogers et al., 2020), two V\textsubscript{H}3-53-derived antibodies isolated from other COVID-19 convalescent donors, to components of the REGN-COV2 antibody cocktail (Baum et al., 2020; Hansen et al., 2020), and to the polyclonal immunoglobulins (IgG) of four out of four healthy convalescent donors we tested. Antibody affinity enhancements, which we performed based on X-ray crystal structures we determined, allowed us to examine the effects of somatic mutations on the interaction interface (Figure 1). The S31N\textsubscript{VH} mutation in C1A-C2 provides new contacts with Q474\textsubscript{RBD} and K458\textsubscript{RBD} (Figure 1A and 1D). Although the A24V\textsubscript{VH} mutation is not at the RBD/Fab interface, it is a pocket-filling mutation that, through interactions with the side chain of F27\textsubscript{VH}, would rigidify CDR H1 in a conformation that is compatible with RBD binding (Figures 1A, 1C, and 1E). The S56T\textsubscript{VH} mutation, found in most of the antibodies, provides additional hydrophobic contacts with the RBD and with neighboring tyrosines on the antibody, and the S56A\textsubscript{VH} mutation in C1A-B12 removes a polar contact with D420\textsubscript{RBD} (Figures 1A and 1F). The N82I\textsubscript{VL} substitution in the two highest affinity binding antibodies, C1A-H6 and C1A-B12, provides a new hydrophobic contact with Y505\textsubscript{RBD} (Figures 1B and 1G).

Although it is impossible to predict germline CDR H3 sequences, we identified a potential mutation located centrally in the D5-18'01 gene segment from which the CDR H3 loop could be derived (Figure 2A) (Brochet et al., 2008). In six out of seven of our clonally related antibodies, the inferred mutation replaces a germline serine with an arginine, for which two rotamers anchor an extensive network of polar interactions with the RBD (Figure 2B). This network includes Q493\textsubscript{RBD}, a residue that is relevant to antibody neutralization escape (see below). To determine the potential contribution of the S100R\textsubscript{A\textsubscript{H}} change to affinity maturation, we generated germline revertant antibodies that contain germline V\textsubscript{H} and V\textsubscript{L} sequences but vary with either having a C1A-gl and C1A-gl* Fabs bound the RBD with affinities of 127 nM and 46 nM, respectively (Figure 3; Table 1). The difference in RBD affinity, C1A-gl and C1A-gl* neutralized infectious SARS-CoV-2 with comparable IC\textsubscript{50} values (Figure 2D; Table 1). Furthermore, C1A-gl and C1A-B12, the most potent neutralizing antibody against infectious SARS-CoV-2, had similar activity against SARS-CoV-2 pseudotypes (Figure 2E). Although RBD affinities varied over a 100-fold for the antibodies we studied (Table 1), we ultimately observed no statistically significant correlation between
RBD binding affinity and infectious SARS-CoV-2 USA-WA1/2020 neutralization (Figure 2F).

**Structural predictions of antibody neutralization escape**

The convergence of nearly identical responses against the RBD in multiple COVID-19 convalescent individuals (Figures S5A and S5B) led us to hypothesize that SARS-CoV-2 could evolve resistance to V<sub>H</sub>3-53/3-66 antibodies as the virus continues to circulate in humans. A recent report described significant evolution of SARS-CoV-2 in an individual receiving profound immunosuppression (Choi et al., 2020). The individual had antiphospholipid syndrome complicated by diffuse alveolar hemorrhage and received glucocorticoids, cyclophosphamide, rituximab, and eculizumab as part of their immunosuppression; they ultimately experienced multiple episodes of symptomatic disease (Choi et al., 2020). COVID-19 was diagnosed on day 0 of infection by RT-PCR, and SARS-CoV-2 whole genome viral sequencing was performed from nasopharyngeal specimens at various time points and up to day 152 (Figure 3A) (Choi et al., 2020). There was evidence of pronounced RBD sequence evolution by the later time points, with a total of eight mutations (Figures 3B and 3C). We predicted that five of these eight mutations would impact C1A-V<sub>H</sub>3-53 antibody binding (Figures 3B and 3C). The Q493K RBD mutation would introduce a substantial clash with CDR H3 residue R100<sub>VH</sub> found in most of the antibody clones (Figures 1A and 4A). C1A-H6 is the only antibody clone that contains a lysine at position 100<sub>VH</sub> (Figure 1A); although we did not obtain a crystal structure of the RBD bound to the C1A-H6 Fab to visualize its contacts, K100<sub>VH</sub> would introduce minor clashes with CDR L1 residue S30<sub>VL</sub>, a V<sub>K</sub>1-9 germine residue (Figures 1B and 4B). This germine residue is conserved in the other V<sub>H</sub>3-53-derived neutralizing antibodies we examined that also contain the V<sub>K</sub>1-9 light chain and for which structures are available (Figures S5A and S5D). Alternate rotamers we observed in our structures for residues R100<sub>VH</sub> and S30<sub>VL</sub> would partially accommodate the Q493K<sub>RBD</sub> and N501Y<sub>RBD</sub> mutations (Figures 4A and 4B). The other mutations (E484K/A<sub>RBD</sub>, F486I<sub>RBD</sub>, and Y489H<sub>RBD</sub>) would alter polar or hydrophobic antibody contacts (Figures 4C–4E). In particular, the Y489H<sub>RBD</sub> change detected on day 128 sequencing would alter an extensive network of polar interactions with antibody residue R94<sub>VH</sub>, a germline antibody residue that is conserved in all V<sub>H</sub>3-53/3-66-derived antibodies (Figures 4E and S5C). Mutations at position E484<sub>RBD</sub>, however, would be better tolerated, because the network of polar interactions with the antibodies, which includes water molecules, would either be lost (E484A<sub>RBD</sub>) or possibly be reorganized (E484K<sub>RBD</sub>) (Figure 4C).

**Evolved spike variants escape V<sub>H</sub>3-53 antibody neutralization**

We next sought to validate our structural predictions for the effects of RBD mutations on V<sub>H</sub>3-53 antibody neutralization using lentivirus pseudotypes bearing variant S proteins. Because variants detected at later time points contained the most RBD mutations, we generated pseudotypes with S proteins that contain mutations observed on days 143–152 (Figures 3B and S6). The original day 146 sequence contains a seven-residue deletion at the N terminus of S1 near the expected signal peptide juncture that is of unclear significance, so we preserved this segment as wild-type for viral pseudotyping (Figure S6). We also retained the Y489H<sub>RBD</sub> mutation found on day 143 given its predicted impact on the antibody-RBD interface and because it has also been detected in additional human-derived SARS-CoV-2 S sequences (Figures 3B and 4E; Table S3), generating S mutants denoted “day 146” and “day 152” (Figure S6). We used D614G<sub>S</sub> pseudotypes as the wild-type control for these experiments because all sequences recovered from the immunocompromised individual included it, suggesting that the initial infecting SARS-CoV-2 virus contained this substitution.

---

Table 1. Summary of C1A-V<sub>H</sub>3-53 antibody binding and neutralization data

| Antibody | Number of a.a. changes (V<sub>H</sub>, V<sub>L</sub>) | Kinetic analysis | SARS-CoV-2 pseudotype IC<sub>50</sub> (μg mL<sup>−1</sup>) | SARS-CoV-2 WA1/2020 IC<sub>50</sub> (μg mL<sup>−1</sup>) |
|----------|---------------------------------|-----------------|-----------------|-----------------|
| C1A-gl   | –                               | 4.41E+04 5.59E−03 127 | 0.098<sup>a</sup> | 0.126 |
| C1A-gfl  | –                               | 1.08E+05 4.95E−03 45.7 | 0.025<sup>a</sup> | 0.102 |
| C1A-B3   | 3, 2                            | 1.04E+05 7.95E−03 76.3 | 0.053 | 0.441 |
| C1A-F10  | 1, 4                            | 4.52E+04 2.51E−03 55.7 | 0.008 | 0.184 |
| C1A-C2   | 3, 6                            | 1.70E+05 2.39E−03 14.1 | 0.118 | 0.132 |
| C1A-H5   | 5, 5                            | 7.27E+04 6.14E−04 8.5 | 0.139 | 0.256 |
| C1A-C4   | 2, 5                            | 5.23E+04 4.09E−04 7.8 | 0.046 | 0.127 |
| C1A-B12  | 1, 3                            | 8.61E+04 3.63E−04 4.2 | 0.081 | 0.062 |
| C1A-H6   | 2, 4                            | 1.13E+05 1.00E−04 0.9 | 0.072 | 0.112 |
| C1A-B12.1| 3, 3                            | 1.60E+05 1.07E−04 0.7 | 0.054<sup>a</sup> | 0.028 |
| C1A-B12.2| 4, 3                            | 1.69E+05 7.51E−05 0.5 | 0.115<sup>a</sup> | 0.025 |
| C1A-B12.3| 5, 3                            | 1.14E+05 6.23E−05 0.5 | 0.090<sup>a</sup> | 0.032 |

a,a., amino acids; ND, not determined.

<sup>a</sup>Measured with D614G<sub>S</sub> lentivirus pseudotypes as reported in Figure 4.
146* and day 152* pseudotypes were neutralized by an ACE2-Fc fusion protein (Figures S7I and S7J) but were resistant to neutralization by C1A-V H3-53 antibodies (Figures 5A, 5B, and S2C). C1A-H6, whose Fab binds the tightest to the RBD (0.9 nM; Table 1), had some activity against the day 152* S pseudotype, but with a 40-fold decrease in potency (IC50 value of 4.5 \mu M) (Figures 5A and S2C).

The Q493K RBD mutation, which was observed in sequences obtained on days 128, 130, and 146 (Figure 3B), has previously been described through in vitro resistance mapping efforts with recombinant vesicular stomatitis virus expressing SARS-CoV-2 S (rVSV-S) (Weisblum et al., 2020). The Q493K RBD change or a similar mutation (Q493R RBD) has also been recently described in other human-derived SARS-CoV-2 sequences (Figure 3B; Table S3). To determine the role of the Q493K/R RBD mutations in resistance to C1A-V H3-53 antibodies, we generated pseudotypes containing either mutation in addition to the D614GS change. We also included an N439K RBD variant, a recently described antibody neutralization escape mutant (Thomson et al., 2021). The Q493K RBD mutation caused substantial resistance to the C1A-V H3-53 antibodies that bind the most weakly to the RBD (Figures 5A and 5B). We observed similar findings with the Q493R RBD pseudotypes, although the decrease in neutralization sensitivity was more severe. An exception to the general observation that...
weaker binding antibodies are less active against mutants was C1A-gl*, which neutralized Q493K/R RBD pseudotypes better than C1A-gl. This is likely because C1A-gl contains a serine instead of an arginine at CDR H3 position 100a, which would better accommodate these RBD mutations (Figure 4A). The N439K RBD mutation had no effect on pseudotype neutralization by C1A-VH3-53 antibodies (Figure 5A), which was expected, because this mutation falls outside of the VH3-53 antibody epitope on the RBD.

To determine if resistance extends to VH3-53-derived antibodies isolated from different COVID-19 convalescent donors, we also tested antibodies B38 (Wu et al., 2020) and CC12.1 (Rogers et al., 2020; Yuan et al., 2020a). The Q493K/R RBD mutations conferred decreased sensitivity to B38 but had no effect on neutralization by CC12.1 (Figures 5C, S2D, and S2E). Day 146* and day 152* S pseudotypes, however, were completely resistant to both of these monoclonal antibodies (Figures 5C, S2D, and S2E).

Resistance to therapeutic antibodies
The monoclonal antibody cocktail REGN-COV2 comprises two antibodies that bind non-overlapping sites on the RBD to suppress the emergence of antibody neutralization escape mutations (Baum et al., 2020; Hansen et al., 2020). REGN10933 binds a region of the RBD that overlaps significantly with the ACE2-binding site, while REGN10987 binds a region that has little to no overlap (Figure 5D). Of the S mutations that evolved during persistent SARS-CoV-2 infection in the immunocompromised individual, the Q493K RBD change, found in day 146 sequencing, was previously detected in tissue cell culture passaging experiments using REGN10933 and rVSV-S (Baum et al., 2020). In our experiments, the Q493K RBD mutation...
decreased REGN10933 pseudotype neutralization potency by 15-fold (Figures 5C and S2D). Day 146* and day 152* pseudotypes, however, were completely resistant (Figures 5C and S2D). Notably, the day 152* variant lacks the Q493K RBD substitution, but its F486I RBD mutation is similar to a known REGN10933 resistance mutation (F486V RBD) (Baum et al., 2020).

The N440D RBD mutation, which was only detected on day 146 sequencing (Figure 3B), falls on the REGN10987 RBD-binding site. It is adjacent to a N439K RBD mutation that is found in circulating variants with reported REGN10987 resistance (Thomson et al., 2021) (Figure 5D). The day 146* variant had a 4-fold decrease in REGN10987 neutralization sensitivity, whereas the N439K RBD mutation caused a 14-fold decrease in sensitivity (Figures 5C and S2D). REGN10987, therefore, is the only antibody we tested that had demonstrable activity against the day 146* S pseudotypes, but a single substitution at an adjacent position (N439K RBD) found in circulating variants (Thomson et al., 2021) could result in additional neutralization escape.

Evolved S variants are resistant to convalescent donor polyclonal IgG

All of the potent SARS-CoV-2 neutralizing antibodies we isolated from the healthy COVID-19 convalescent donor (C1) were clonotypes of a single VH3-53/VK1-9 antibody, suggesting that this individual’s memory B cell response was narrowly focused on this class of neutralizing antibodies (Figure S1; Table S1). Although purified C1 IgG could neutralize WT (D614G S) pseudotypes, days 146* and 152* S pseudotypes were resistant to C1 serum IgG neutralization (Figures 6A and 6B). The Q493K RBD mutation also conferred near complete resistance to C1 IgG (Figures 6A and 6B). The N439K RBD mutation (Thomson et al., 2021), an escape mutation that falls outside of the RBD epitope for
VH3-53-derived neutralizing antibodies, had no effect on C1 polyclonal IgG neutralization (Figures 6A and 6B). To determine whether our findings extended to other COVID-19 convalescent donors that may have less epitope biased antibody responses, we performed similar experiments with purified IgG from three additional donors ("C2," "C3," and "C4"). The neutralizing activity of purified IgG from these donors was mostly unaffected by the single mutations (Q493K/R RBD or N439K RBD), but day 146* and day 152* S pseudotypes were resistant to neutralization (Figures 6A and 6B).

VH3-53 antibody affinity maturation partially overcomes neutralization escape

Although the benefits of antibody RBD affinity are limited in SARS-CoV-2 USA-WA1/2020 neutralization (Figure 2F), affinity gains, in principle, could compensate for losses of contacts or potential clashes that are caused by escape mutations. Indeed, the highest affinity binding antibodies were seemingly the least impacted by neutralization escape mutations (Figures 5A, 5B, and S2C). We selected C1A-B12, our most potent neutralizing antibody against infectious SARS-CoV-2 (Table 1), to directly test whether...
neutralizing antibodies. Perhaps the most striking finding is ACE2 while escaping neutralization by major classes of human 2020), suggest that SARS-CoV-2 can evolve solutions to bind containing the most mutations, C1A-B12.3, was the most potent (IC $_ {50}$ < 0.5  m$ ^ {3} $). Previous work from our laboratory, however, had less of an effect on the serum IgG of three additional COVID-19 convalescent donors (Figures 6A and 6B), suggesting that the C1 donor may be a rare example of an overly focused antibody response.

The immunocompromised individual we studied received REGN-COV2 (REGN10933 and REGN10987) on day 145 of their illness, so the S mutations detected on days 146 and 152 could have been influenced by selective pressure from this therapeutic antibody cocktail, as described in a recent report (Starr et al., 2021). Nonetheless, several of the RBD mutations we studied were detected before day 146 (Figure 3B), suggesting that they could have arisen through selective pressure from the individual’s weakened neutralizing antibody response (Choi et al., 2020). Furthermore, based on publicly available sequences as of February 19, 2021 in the GISAID database (Elbe and Buckingham-Merrett, 2017), seven of the eight RBD mutations we examined in the immunocompromised individual have been detected in additional human-derived SARS-CoV-2 sequences (Figure 3B; Table S3). The only unique mutation is F486L RBD, although a nearly identical mutation, F486L RBD, has been observed in another human-derived SARS-CoV-2 S sequence (Table S3).

Interestingly, two of the residues we pinpointed in our analysis (Q493R RBD and N501Y RBD) are in the equivalent hotspot positions reported in the GISAID database, albeit with very low frequency for the time being (Figure 3B; Table S3). Additional mutations that we did not study directly but that could also substantially impact neutralization by Vh3-53-derived antibodies are the K417N Vh3-53/3-66 antibodies, including antibodies described elsewhere (Hurlburt et al., 2020; Wu et al., 2020) (Figures 5A–5G). Fabs for the resulting antibodies (C1, C2, C3, and C4) or that of a control, non-immune donor (“ctrl”). Means ± standard deviation from two experiments performed in triplicate (n = 6) are shown.

(B) Table showing IC$_{50}$ values for pseudotype neutralization tests shown in (A). See also Table S4.

Figure 6. Neutralization escape from convalescent donor polyclonal serum IgG
(A) Dose response neutralization assay with the indicated SARS-CoV-2 S pseudotypes with polyclonal serum IgG of four COVID-19 convalescent donors (C1, C2, C3, and C4) or that of a control, non-immune donor (“ctrl”). Means ± standard deviation from two experiments performed in triplicate (n = 6) are shown. (B) Table showing IC$_{50}$ values for pseudotype neutralization tests shown in (A). See also Table S4.

Additional affinity enhancing mutations could overcome neutralization escape. To generate affinity enhanced versions of C1A-B12, we introduced into its sequence somatic hypermutation changes found in other Vh3-53/3-66 antibodies, including antibodies described elsewhere (Hurlburt et al., 2020; Wu et al., 2020) (Figures 5A–5G). Fabs for the resulting antibodies (C1A-B12.1, C1A-B12.2, and C1A-B12.3) bound to the RBD with a 6- to 10-fold increase in affinity as compared to the parent C1A-B12 Fab (Figure S3; Table 1). Affinity enhanced variants potently neutralized D614GS pseudotypes and infectious SARS-CoV-2 (Figures 5A, 5B, 5C, and 5D; Table 1). Remarkably, although C1A-B12 had no activity against day 152 S pseudotype, all three affinity optimized versions were active; the antibody containing the most mutations, C1A-B12.3, was the most potent (IC$_{50}$ < 0.5  m$ ^ {3} $) (Figures 5A, 5B, and 5C). Day 146 S pseudotype, however, was still resistant to neutralization by the affinity enhanced antibodies (Figures 5A, 5B, and 5C).

DISCUSSION

Our finding that the day 146 and day 152 S pseudotypes escape neutralization by all unmodified Vh3-53 antibodies we tested and REGN10933, an antibody derived from a different germline gene (Vh3-11) (Baum et al., 2020; Hansen et al., 2020), suggest that SARS-CoV-2 can evolve solutions to bind ACE2 while escaping neutralization by major classes of human neutralizing antibodies. Perhaps the most striking finding is that the polyclonal antibody response in a convalescent individual we studied (C1) is so focused on an RBD epitope that single mutations (Q493K RBD) can confer substantial resistance to serum IgG neutralization (Figures 6A and 6B). The Q493K RBD mutations, however, had less of an effect on the serum IgG of three additional COVID-19 convalescent donors (Figures 6A and 6B), suggesting that the C1 donor may be a rare example of an overly focused antibody response.

The immunocompromised individual we studied received REGN-COV2 (REGN10933 and REGN10987) on day 145 of their illness, so the S mutations detected on days 146 and 152 could have been influenced by selective pressure from this therapeutic antibody cocktail, as described in a recent report (Starr et al., 2021). Nonetheless, several of the RBD mutations we studied were detected before day 146 (Figure 3B), suggesting that they could have arisen through selective pressure from the individual’s weakened neutralizing antibody response (Choi et al., 2020). Furthermore, based on publicly available sequences as of February 19, 2021 in the GISAID database (Elbe and Buckingham-Merrett, 2017), seven of the eight RBD mutations we examined in the immunocompromised individual have been detected in additional human-derived SARS-CoV-2 sequences (Figure 3B; Table S3). The only unique mutation is F486L RBD, although a nearly identical mutation, F486L RBD, has been observed in another human-derived SARS-CoV-2 S sequence (Table S3).

Interestingly, two of the residues we pinpointed in our analysis (Q493R RBD and N501Y RBD) are in the equivalent hotspot positions reported in the GISAID database, albeit with very low frequency for the time being (Figure 3B; Table S3). Additional mutations that we did not study directly but that could also substantially impact neutralization by Vh3-53-derived antibodies are the K417N Vh3-53/3-66 antibodies, including antibodies described elsewhere (Hurlburt et al., 2020; Wu et al., 2020) (Figures 5A–5G). Fabs for the resulting antibodies (C1, C2, C3, and C4) or that of a control, non-immune donor (“ctrl”). Means ± standard deviation from two experiments performed in triplicate (n = 6) are shown.

(B) Table showing IC$_{50}$ values for pseudotype neutralization tests shown in (A). See also Table S4.

Figure 6. Neutralization escape from convalescent donor polyclonal serum IgG
(A) Dose response neutralization assay with the indicated SARS-CoV-2 S pseudotypes with polyclonal serum IgG of four COVID-19 convalescent donors (C1, C2, C3, and C4) or that of a control, non-immune donor (“ctrl”). Means ± standard deviation from two experiments performed in triplicate (n = 6) are shown. (B) Table showing IC$_{50}$ values for pseudotype neutralization tests shown in (A). See also Table S4.
The SARS-CoV-2 Q493K_RBD change is also involved in adaptation to murine ACE2 (Leist et al., 2020) and is analogous to the SARS-CoV N479K_RBD mutation, which allows preferential engagement of palm civet ACE2 (host reservoir) over human ACE2 (Li et al., 2005b; Wu et al., 2012). The RBD sequence changes we studied, therefore, are likely a combination of neutralizing antibody escape mutations and adaptations to human ACE2 binding.

In certain instances, antibody escape mutations could also negatively impact ACE2 binding. Although D614G and day 146 S pseudotypes had comparable IC_{50} values in neutralization tests with an ACE2-Fc fusion protein, day 152 S pseudotype typically had a more than a 10-fold increase, with some variability in the absolute value depending on the experiment (Figures 5A, 5C, S7I, and S7J). These observations suggest that the affinity of the day 152* S for ACE2 may have been compromised. A loss in receptor-binding affinity for the day 152* S may be explained by the F486IRBD mutation it contains, which would remove prominent hydrophobic contacts with ACE2 (Figure S7F). Although we used pseudotypes for our studies and focused on the RBD, additional studies with authentic viruses will be required to determine the consequences of the S mutations we studied on viral fitness and potential for transmission. For example, it is unclear how a deletion detected at the S1 N terminus/signal peptide juncture on the original day 146 sequence (Figure S6) would impact S processing, and whether potentially decreased ACE2 binding by a day 152*-like S variant would affect viral replication and transmission.

Although these were not the focus of our studies, non-RBD binding neutralizing antibodies can target the SARS-CoV-2 S1 NTD. 4A8, an antibody isolated from a COVID-19 convalescent individual, is a representative member of this class (Chi et al., 2020). Examination of late-stage evolved S sequences reveal that they contain internal deletions within the S NTD (spanning residues 141–144) that would disrupt part of 4A8’s epitope (Figures S6, S7K, and S7L). The deletions would also reposition a nearby N-linked glycan and potentially block 4A8 epitope access (Figure S7L). A recent report described persistent SARS-CoV-2 infection in another immunocompromised individual who had acquired hypogammaglobulinemia, with detectable viral RNA more than 100 days after infection (Avanzato et al., 2020). In this individual, S evolution also led to a deletion of a similar segment in the S1 NTD (spanning residues 139–145) (Avanzato et al., 2020). Notably, S1 NTD deletions found in the B.1.1.7 and B.1.351 S variants are in, or near, the NTD deletion found in the S mutants we studied (Figures S6, S7K, and S7L). Although NTD internal deletions could substantially impact 4A8 neutralization, we could not directly test this hypothesis, because 4A8 has very weak neutralizing activity against S lentivirus pseudotypes on HEK293T cells overexpressing human ACE2 (Chi et al., 2020), which we used in our assays.

The value of our study and additional studies examining immune responses in immunocompromised individuals (Kemp et al., 2021; Starr et al., 2021) is obtaining insight from a dynamic immune system over time as opposed to only studying viral escape mutations in vitro. In vitro studies have indeed been highly informative in predicting the range of S mutations that can be acquired for antibody neutralization escape, but studying S sequence evolution during persistent SARS-CoV-2 infection may help highlight the mutations that have the most potential to spread in emerging variants.

Although single mutations are unlikely to confer substantial resistance to polyclonal antibody responses in many individuals, multiple mutations, as are observed in the late stage evolved S variants we studied, are likely to have an impact. To fully understand the consequences of SARS-CoV-2 S genetic drift, including its potential implication to ongoing vaccination campaigns, our study underscores the importance of studying multiple mutations that can concomitantly be found in S, as opposed to single S mutations in isolation.

**Limitations of study**

The S mutations we studied are only from one immunocompromised individual (n = 1) (Choi et al., 2020). Although some of the S mutations we mention in our work are also now found in other human-derived SARS-CoV-2 sequences available in public databases (e.g., B.1.1.7 variants containing the Q493K/R_RBD mutations; see Table S3), these variants for the time being are rare, and the context in which they arose is also not defined based on public information (e.g., whether they occurred in a healthy person or an immunocompromised individual, or whether the individual received treatment with convalescent plasma or therapeutic antibodies prior to sampling, etc.). Although we used infectious SARS-CoV-2 in some assays, we used replication-defective pseudotyped lentiviruses as a surrogate system for studying the effects of S mutations. The replication fitness of infectious SARS-CoV-2 carrying the S mutations we studied remains to be determined. We used multiple V_{H}3-53-derived monoclonal antibodies isolated from a healthy donor (n = 1), and single antibodies from two additional donors (B38 from Wu et al. [2020] and CC12.1 from Rogers et al. [2020]) but did not test all V_{H}3-53-derived monoclonal antibodies identified to date. Other V_{H}3-53-derived antibodies may be differently impacted by specific mutations because of differences in their light chain genes and CDR H3 loops. Last, although we predicted that residue R100a_{VH} was a serine in the germline C1A-V_{H}3-53 antibody based on our analysis using the IMGT/V-QUEST database (Brochet et al., 2008), this database is likely missing alleles. To prove that our D gene assignment was accurate, we would have had to sequence D gene segments in PBMC donor C1, and we did not perform this analysis. There is, therefore, the possibility that an arginine or lysine would be found at position 100a_{VH} in a germline C1A-V_{H}3-53 antibody.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
We worked to ensure gender balance in the recruitment of human subjects. We worked to ensure ethnic or other types of diversity in the recruitment of human subjects. We worked to ensure that the study questionnaires were prepared in an inclusive way. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science. One or more of the authors of this paper received support from a program designed to increase minority representation in science. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work.

Received: December 2, 2020
Revised: February 23, 2021
Accepted: March 11, 2021
Published: March 16, 2021

REFERENCES

Abraham, J. (2020). Passive antibody therapy in COVID-19. Nat. Rev. Immunol. 20, 401–403.
Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221.
Aricescu, A.R., Lu, W., and Jones, E.Y. (2006). A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr. D Biol. Crystallogr. 62, 1243–1250.
Avanzato, V.A., Matson, M.J., Seifert, S.N., Pryce, R., Williamson, B.N., Anzick, S.L., Barbian, K., Judson, S.D., Fischer, E.R., Martens, C., et al. (2020). Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell 183, 1901–1912.
Baum, A., Fulton, B.O., Wloka, E., Copin, R., Pascal, K.E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., et al. (2020). Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014–1018.
Bricogne, G., Blan, E., Brandl, M., Flensburg, C., Keller, P., Paciorek, W., Roversi, P., Sharto, A., Smart, O.S., Vonrhein, C., et al. (2017). BUSTER version 2.10.3 (Global Phasing Ltd.).
Brochet, X., Lefranc, M.P., and Giudicelli, V. (2008). IMGT/QUEST: the highly customized and integrated system for IGH and TR standard V-J and V-D-J sequence analysis. Nucleic Acids Res. 36, W503-8.
Chen, S., Sanjana, N.E., Zheng, K., Shalem, O., Lee, K., Shi, X., Scott, D.A., Song, J., Pan, J.Q., Weissleder, R., et al. (2013). Genome-wide CRISPR screen in a mouse model of tumour growth and metastasis. Cell 150, 1246–1260.
Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Deng, Y., Yang, Y., et al. (2020). A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650–655.
Choi, B., Choudhary, M.C., Regan, J., Sparks, J.A., Padera, R.F., Ou, X., Solomon, I.H., Kuo, H.H., Boucau, J., Bowman, K., et al. (2020). Persistence and evolution of SARS-CoV-2 in an immunocompromised host. Nat. Engl. J. Med. 383, 2291–2293.
Clark, L.E., Mahmutovic, S., Raymond, D.D., Dilanyan, T., Koma, T., Manning, J.T., Shankar, S., Lewis, S.C., Briggle, A.M., Enna, D.A., et al. (2018). Vaccine-elicted receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses. Nat. Commun. 9, 1884.
Denison, M.R., Graham, R.L., Donaldson, E.F., Eckerle, L.D., and Baric, R.S. (2011). Coronavirus: an RNA proofreading machine regulates fidelity and diversity. RNA Biol. 8, 270–279.
Du, S., Cao, Y., Zhu, Q., Yu, P., Qi, F., Wang, G., Du, X., Bao, L., Deng, W., Zhu, H., et al. (2020). Structurally resolved SARS-CoV-2 antibody shows high efficiency in severely infected hamsters and provides a potent cocktail pairing strategy. Cell 183, 1013–1023.e13.
Elbe, S., and Buckland-Merrett, G. (2017). Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob. Chall. 1, 33–46.
Evans, P.R., and Murshudov, G.N. (2013). How good are my data and what is the resolution? Acta Crystallogr. D Biol. Crystallogr. 69, 1204–1214.

Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y.Q., Wang, Y., Teng, Y., Zhao, Z., Cui, Y., et al. (2020). Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 369, 1603–1607.

Hansen, J., Baum, A., Pascai, K.E., Russo, V., Giordano, S., Wloga, E., Fulton, B.O., Yan, Y., Koon, K., Patel, K., et al. (2020). Studied in humanized mice and convalvescent yields a SARS-CoV-2 antibody cocktail. Science 369, 1010–1014.

Harcourt, J., Tamin, A., Lu, X., Kamili, S., Sakthivel, S.K., Murray, J., Queen, K., Tao, Y., Paden, C.R., Zhang, J., et al. (2020). Severe Acute Respiratory Syndrome Coronavirus 2 from patient with coronavirus disease, United States. Emerg. Infect. Dis. 26, 1266–1273.

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T.S., Herrler, G., Wu, N.H., Nitsche, A., et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e6.

Hurlburt, N.K., Seydoux, E., Wan, Y.H., Edara, V.V., Stuart, A.B., Feng, J., Suthar, M.S., McGuire, A.T., Stamatatos, L., and Pancera, M. (2020). Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. Nat. Commun. 11, 5413.

Jones, T.A., Zou, J.Y., Cowan, S.W., and Kjeldgaard, M. (1991). Improved methods for building protein models in electron density maps and the location of multiple epitopes on SARS-CoV-2 spike. Nature 584, 437–442.

Kabash, W. (2010). Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132.

Kemp, S.A., Collier, D.A., Datir, R.P., Ferreira, I.A.T.M., Gayed, S., Jahun, A., Mahmutovic, S., Clark, L., Levis, S.C., Briggiler, A.M., Enria, D.A., Harrison, M.S., and Read, R.J. (2007). Phaser crystallographic software. J. Appl. Cryst. 40, 658–674.

Radoszitzyk, S.R., Abraham, J., Spiropoulou, C.F., Kuhn, J.H., Nguyen, D., Li, W., Negel, J., Schmidt, P.J., Nunberg, J.H., Andrews, N.C., et al. (2007). Transferrin receptor 1 is a cellular receptor for New World hemorrhagic fever arenaviruses. Nature 446, 92–96.

Robbiani, D.F., Gaebler, C., Muecksch, F., Lorenzi, J.C.C., Wang, Z., Cho, A., Agudelo, M., Barnes, C.O., Gazumyan, A., Finkin, S., et al. (2020). Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437–442.

Robert, X., and Gouet, P. (2014). Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 42, W320–4.

Rogers, T.F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020). Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369, 956–963.

Scheid, J.F., Mouquet, H., Feldhahn, N., Walker, B.D., Pereyra, F., Cutrell, E., Seaman, M.S., Mascola, J.R., Wyatt, R.T., Wardemann, H., and Nussenzweig, M.C. (2009). A method for identification of HIV gp140 binding memory B cells in human blood. J. Immunol. Methods 343, 65–87.

Scheid, J.F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T.Y., Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., et al. (2011). Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633–1637.

Seydoux, E., Homad, L.J., MacCamy, A.J., Parks, K.R., Hurlburt, N.K., Jennewein, M.F., Akins, N.R., Stuart, A.B., Wan, Y.H., Feng, J., et al. (2020). Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity 53, 98–105.e6.

Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., and Li, F. (2020). Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221–224.

Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020). A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120–124.

Starr, T.N., Greaney, A.J., Addetta, A., Hannon, W.W., Choudhary, M.C., Dingens, A.S., Li, J.Z., and Bloom, J.D. (2021). Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371, 850–854.

Sui, J., Aird, D.R., Tamin, A., Murakami, A., Yan, M., Yammanuru, A., Jing, H., Kan, B., Liu, X., Zhu, Q., et al. (2008). Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog. 4, e1000197.

Thomson, E.C., Rosen, L.E., Shepherd, J.G., Spreafico, R., da Silva Filipe, A., Wojcechowskyj, A.J., Davis, C., Piccoli, L., Pascall, D.J., Dillen, J., et al.: ISARIC4C Investigators; COVID-19 Genomics UK (COG-UK) Consortium (2021). SARS-CoV-2 evolution during treatment of chronic infection. Nature. Published online February 5, 2021. https://doi.org/10.1038/s41586-021-03291-y.

Krammer, F. (2020). SARS-CoV-2 vaccines in development. Nature 586, 516–527.

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, G., Shi, X., Wang, Q., Zhang, L., and Wang, X. (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220.

Lefranc, M.-P., and Lefranc, G. (2001). The Immunoglobulin FactsBook (Elsevier).

Leist, S.R., Dinnon, K.H., 3rd, Schafer, A., Tse, L.V., Okuda, K., Hou, Y.J., West, A., Edwards, C.R., Sanders, W., Fritch, E.J., et al. (2020). A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 173, 1070–1085.e12.

Li, F., Li, W., Farzan, M., and Harrison, S.C., (2005a). Structure of SARS coronavirus spike receptor-binding domain complex with receptor. Science 309, 1864–1868.

Li, W., Zhang, C., Sui, J., Kuhn, J.H., Moore, M.J., Luo, S., Wong, S.K., Huang, I.C., Xu, K., Vasilieva, N., et al. (2005b). Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 24, 1634–1643.

Liu, L., Wang, P., Nair, M.S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J.F., Sahi, V., Figueroa, A., et al. (2020). Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450–456.

Mahrmutovic, S., Clark, L., Levis, S.C., Briggsler, A.M., Enria, D.A., Harrison, S.C., and Abraham, J. (2015). Molecular basis for antibody-mediated neutralization of New World Hemorrhagic fever mammaeaviruses. Cell Host Microbe 18, 705–713.

McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, R.J. (2007). Phaser crystallographic software. J. Appl. Cryst. 40, 658–674.

Please cite this article in press as: Clark et al., SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. Cell (2021), https://doi.org/10.1016/j.cell.2021.03.027
Yuan, M., Wu, N.C., Zhu, X., Lee, C.D., So, R.T.Y., Lv, H., Mok, C.K.P., and Wilson, I.A. (2020b). A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630–633.

Yurkovetskiy, L., Wang, X., Pascal, K.E., Tomkins-Tinch, C., Nyalile, T.P., Wang, Y., Baum, A., Diehl, W.E., Dauphin, A., Carbone, C., et al. (2020). Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell 183, 739–751.e8.

Zhang, Q., Honko, A., Zhou, J., Gong, H., Downs, S.N., Vasquez, J.H., Fang, R.H., Gao, W., Griffiths, A., and Zhang, L. (2020). Cellular nanospheres inhibit SARS-CoV-2 infectivity. Nano Lett. 20, 5570–5574.

Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273.
## STAR METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| anti-IgG-APC        | BD Biosciences | Cat# 550931; RRID: AB_398478 |
| anti CD19-FITC      | BD Biosciences | Cat# 340864; RRID: AB_400152 |
| anti-human Fc-HRP   | Sigma-Aldrich | Cat# A0170; RRID: AB_257868 |
| **Bacterial and virus strains** | | |
| SARS-CoV-2 USA-WA1/2020 | Harcourt et al., 2020 | N/A |
| **Biological samples** | | |
| PBMC and plasma from SARS-CoV-2 convalescent donors | This paper | N/A |
| **Chemicals, peptides, and recombinant proteins** | | |
| Recombinant SARS-CoV-2 spike (“S2P”) | This paper | N/A |
| Recombinant SARS-CoV-2 RBD | This paper | N/A |
| TEV protease | This paper | N/A |
| BirA ligase | This paper | N/A |
| Streptavidin-PE | Invitrogen | Cat# S866 |
| Ni Sepharose Excel | GE Healthcare | Cat# 17-3712-02 |
| Human ACE2-Fc fusion protein | This study | N/A |
| MabSelect SuRE Resin | GE Healthcare | Cat# 97067-944 |
| Kifunensine | Sigma-Aldrich | Cat# K1140 |
| Peg/Ion Screen | Hampton | HR2-126 |
| Peg/Ion 2 Screen | Hampton | HR2-098 |
| Pierce Protein G Ultra Link Resin | Thermo Fisher Scientific | Cat# 53126 |
| PEGRx 1 Screen | Hampton | HR2-082 |
| PEGRx 2 Screen | Hampton | HR2-084 |
| **Critical commercial assays** | | |
| SuperScript™ III reverse transcriptase | Invitrogen | Cat# 18080044 |
| Expifectamine 293 Transfection Kit | Thermo Fisher Scientific | Cat# A14525 |
| Lipofectamine 3000 | Thermo Fisher Scientific | Cat# L3000150 |
| **Deposited data** | | |
| Crystal structure of C1A-B3/RBD complex | This paper | PDB: 7KFW |
| Crystal structure of C1A-F10/RBD complex | This paper | PDB: 7KFY |
| Crystal structure of C1A-C2/RBD complex | This paper | PDB: 7KFY |
| Crystal structure of C1A-B12/RBD complex | This paper | PDB: 7KFV |
| **Experimental models: Cell lines** | | |
| HEK293T cells | ATCC | CRL-11268; RRID:CVCL_1926 |
| HEK293T-hACE2 | Michael Farzan | N/A |
| HEK293S Gnti−/− cells | ATCC | CRL-3022; RRID:CVCL_A785 |
| Vero E6 C1008 cells | ATCC | ATCC CRL-1586; RRID:CVCL_0574 |
| Exp293F cells | ThermoFisher | Cat#A14527; RRID: CVCL_D615 |
| Exp293F SARS-CoV-2 S2P-His6 | Bing Chen | N/A |
| **Oligonucleotides** | | |
| Primers for B cell receptor nested PCR and sequencing | Scheid et al., 2011 | N/A |

(Continued on next page)
Continued

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Recombinant DNA     |        |            |
| SARS-CoV-2 S2P      | This paper | N/A        |
| CR3022 Fab          | Galit Alter | GenBank: DQ168569.1 and DQ168570.1 |
| 4A8                 | Chi et al., 2020 | Sequence from PDB: 7C2L |
| B38                 | Wu et al., 2020 | Sequence from PDB: 7BZ5 |
| CC12.1              | (Yuan et al., 2020a) | Sequence from PDB: 6XC2 |
| REGN10933           | Hansen et al., 2020 | Sequence from PDB: 6XDG |
| REGN10987           | Hansen et al., 2020 | Sequence from PDB: 6XDG |
| Human ACE2          | Michael Farzan, Hyeryun Choe | N/A |
| Codon optimized SARS-CoV-2 S pCAGGS | This paper | N/A |
| Codon optimized SARS-CoV-2 S D614G pCAGGS | This paper | N/A |
| Codon optimized SARS-CoV-2 S D614G N439K pCAGGS | This paper | N/A |
| Codon optimized SARS-CoV-2 S D614G Q493K pCAGGS | This paper | N/A |
| Codon optimized SARS-CoV-2 S D614G Q493R pCAGGS | This paper | N/A |
| Codon optimized SARS-CoV-2 S day 146* pCAGGS | This paper | N/A |
| Codon optimized SARS-CoV-2 S day 152 pCAGGS | This paper | N/A |
| VSV G pCAGGS        | Radoshitzky et al., 2007 | N/A |
| psPAX2              | Didier Trono | Addgene Cat#63592 |
| lentiCas9-EGFP      | Chen et al., 2015 | Addgene Cat#63592 |

Software and algorithms

| Software and algorithms | Source | RRID |
|-------------------------|--------|------|
| IMGT/V-QUEST            | http://www.imgt.org | N/A |
| ForteBio data analysis software | ForteBio | N/A |
| FlowJo version 10.6.2   | FlowJo | https://www.flowjo.com; RRID:SCR_008520 |
| XDS build 202 00131     | Kabsch, 2010 | https://xds.mpg.de; RRID:SCR_015652 |
| AIMLESS v0.5.32         | Evans and Murshudov, 2013 | http://legacy.ccp4.ac.uk/html/aimless.html; RRID:SCR_015747 |
| Phaser v2.8.3           | McCoy et al., 2007 | https://www.phenix-online.org/documentation/reference/phaser.html; RRID:SCR_014219 |
| Phenix v1.18.2-3874     | Adams et al., 2010 | https://www.phenix-online.org; RRID:SCR_014224 |
| Buster v2.10.3          | Bricogne et al., 2017 | https://www.globalphasing.com/buster; RRID:SCR_015653 |
| Prism v8.4.3            | GraphPad Software | https://www.graphpad.com; RRID:SCR_002798 |
| O v15.0                 | Jones et al., 1991 | N/A |

Other

| Other                  | Source | RRID |
|------------------------|--------|------|
| anti-CD20 MicroBeads   | Miltenyi Biotec | Cat#130-091-104 |
| MACS LS column         | Miltenyi Biotec | Cat#130-042-401 |
| anti-FLAG M2 Affinity Gel | Sigma-Aldrich | Cat# A2220; RRID: AB_10063035 |
| Protein G UltraLink    | Thermo Fisher Scientific | Cat#: S3125 |
| MabSelect SuRE Resin   | GE Healthcare | Cat# 17547401 |
| Streptavidin biosensor | ForteBio | Cat# 18-5020 |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jonathan Abraham (jonathan_abraham@hms.harvard.edu).

Materials availability
Unique reagents generated in this study are available from the Lead Contact upon request with completed material transfer agreements (MTA). GISAID accession numbers for the sequences analyzed in Figure 3 are provided in Figure S6 and Table S3.

Data and code availability
All relevant data are available from the authors upon request. Protein Data Bank (PDB) identification numbers for the C1A-B3/RBD, C1A-F10/RBD, C1A-C2/RBD, and C1A-B12 RBD complexes are PDB: 7KFW, 7KFY, 7KFX, and 7KFV, respectively.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Donors
This study was approved by the Harvard Medical School Office of Human Research Administration Institutional Review Board (IRB20-0365) as was the use of healthy donor control blood (IRB19-0786). We received informed, written consent from healthy adult males (n = 3) and a female (n = 1) participants who recovered from confirmed SARS-CoV-2 infection, with mild illness not requiring hospitalization more than five weeks before blood donation. We isolated C1, C2, C3, C4 and control donor plasma and PBMCs by Ficoll-Plaque (GE Healthcare) density centrifugation. C1 is an adult male who was infected with SARS-CoV-2 five weeks prior to blood donation.

Cells and viruses
We maintained HEK293T cells (ATCC CRL-11268; sex/gender: female; RRID: CVCL_1926) in Dulbecco’s Modified Eagle’s Medium (DMEM) (Thermo Fisher Scientific Cat# 10313039) supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin-streptomycin (Thermo Fisher Scientific Cat# 15140163) and Exp293F™ cells (Thermo Fisher Scientific Cat# A14527; sex/gender: female; RRID: CVCL_D615) in Exp293™ expression medium (Thermo Fisher Scientific Cat# A1435102) supplemented with 1% (v/v) penicillin-streptomycin at 37°C. We maintained HEK293T cells grown in suspension in FreeStyle 293 Expression Medium (Thermo Fisher Scientific Cat# 12338026) and HEK293S GnTI−/− cells (ATCC CRL-3022; sex/gender: female; RRID: CVCL_A785) in Freestyle 293 Expression Medium supplemented with 2% (v/v) ultra-low IgG FBS (Thermo Fisher Scientific Cat# 16250078) at 37°C. A HEK293T-hACE2 stable cell line (sex/gender: female) was a gift from Huihui Mou and Michael Farzan and we maintained these cells in DMEM supplemented with 10% (v/v) FBS, 25 mM HEPES, 1% (v/v) penicillin-streptomycin and 1 μg ml⁻¹ puromycin at 37°C. An Exp293F-His6-tagged SARS-CoV-2 S2P stable cell line (sex/gender: female) was a gift from Bing Chen. We maintained these cells as adherent cells in DMEM supplemented with 1% (v/v) GlutaMax (Thermo Fisher Scientific Cat# 35050079), 1% (v/v) penicillin-streptomycin, 10% (v/v) FBS and 1 μg ml⁻¹ puromycin (Thermo Fisher Scientific Cat# A11138-03) at 37°C. The cell line was then adapted to suspension culture and maintained in Exp293™ expression medium supplemented with 1% (v/v) penicillin-streptomycin and 1 μg ml⁻¹ puromycin at 37°C. All cell lines were obtained from commercial vendors with the exception of the Exp293F-His6-tagged SARS-CoV-2 S2P and HEK293T-hACE2 stable cell lines and were not authenticated. We confirmed the absence of mycoplasma in all cell lines through monthly testing using an e-Mycro PCR detection kit (Bulldog Bio Cat# 25234).

Passage 4 SARS-CoV-2 USA-WA1/2020 (Harcourt et al., 2020) was received from the University of Texas Medical Branch. A T225 flask of Vero E6 cells was inoculated with 90 μl starting material in 15 mL DMEM containing 2% (v/v) of heat inactivated FBS, 25 mM HEPES, 1% (v/v) penicillin-streptomycin and 1 μg ml⁻¹ puromycin at 37°C. An Exp293F-His6-tagged SARS-CoV-2 S2P stable cell line (sex/gender: female) was a gift from Bing Chen. We maintained these cells as adherent cells in DMEM supplemented with 1% (v/v) GlutaMax (Thermo Fisher Scientific Cat# 35050079), 1% (v/v) penicillin-streptomycin, 10% (v/v) FBS and 1 μg ml⁻¹ puromycin (Thermo Fisher Scientific Cat# A11138-03) at 37°C. The cell line was then adapted to suspension culture and maintained in Exp293™ expression medium supplemented with 1% (v/v) penicillin-streptomycin and 1 μg ml⁻¹ puromycin at 37°C. All cell lines were obtained from commercial vendors with the exception of the Exp293F-His6-tagged SARS-CoV-2 S2P and HEK293T-hACE2 stable cell lines and were not authenticated. We confirmed the absence of mycoplasma in all cell lines through monthly testing using an e-Mycro PCR detection kit (Bulldog Bio Cat# 25234).
METHOD DETAILS

Single B cell sorting and antibody cloning
We stained and sorted single memory B cells as previously described (Scheid et al., 2009) using a MoFlo Astrios EQ Cell Sorter (Beckman Coulter). Briefly, we enriched B cells by incubating PBMCs with anti-CD20 MicroBeads (Miltenyi Biotec Cat# 130-091-104) followed by magnetic separation on a MACS LS column (Miltenyi Biotec Cat# 130-042-401) according to the manufacturer’s instructions. We washed, counted, and resuspended the B cells in phosphate buffered saline (PBS) containing 2% (v/v) FBS. We adjusted the B cells to a density of 1x10⁷ cells and incubated cells with biotinylated SARS CoV-2 spike (S2P) at a concentration of 5 μg ml⁻¹ on ice for 30 min. After washing three times and resuspending the cells, we added anti-IgG-APC antibody (BD Biosciences Cat# 559031; RRID: AB_398478), anti-CD19-FITC antibody (BD Biosciences Cat# 340864; RRID: AB_400152), and streptavidin-PE (Invitrogen Cat# S866). After incubating the cells on ice for 30 min, we washed the cells three times in PBS containing 2% (v/v) FBS and passed the suspension through a cell strainer before sorting.

We performed single cell cDNA synthesis using SuperScript™ III reverse transcriptase (Invitrogen Cat# 18080444) followed by nested PCR amplification to obtain the IgH, IgL, and IgK and IgG variable segments from memory B cells as previously described (Scheid et al., 2011). We used IMGT/V-QUEST (Brochet et al., 2008) (http://www.imgt.org) to analyze IgG gene usage and the extent of variable segment somatic hypermutation. The variable segments were cloned into the pVRC8400 vector for expression of the IgG and Fab constructs as previously described (Clark et al., 2018).

Protein production
For single B cell sorting we cloned a construct comprising human codon optimized SARS-CoV-2 S (GenBank ID: QHD43416.1 residues 16-1208) with a “GSAS” substitution at the furin cleavage site (residues 682-685), stabilized in the prefusion conformation through proline substitutions at residues 986 and 987 (Wrap et al., 2020), and a C-terminal foldon trimerization motif followed by a BirA ligase site, a Tobacco Etch Virus (TEV) protease site, a FLAG tag, and a His₁₄₅-tag into the pHLsec vector (Aricescu et al., 2006), which contains its own secretion signal sequence. We note that two N-terminal S residues (residues 14 and 15) downstream of the native S signal peptide were inadvertently omitted from the S2P construct during subcloning. We transfected Expi293F™ cells using an ExpiFectamine™ transfection kit (Thermo Fisher Scientific Cat# A14525) according to the manufacturer’s protocol. We purified the protein using anti-FLAG M2 Affinity Gel (Sigma-Aldrich Cat# A2220; RRID: AB_10063035) according to manufacturer’s protocol and removed the FLAG tag and His₁₄₅-tag with TEV digestion followed by reverse nickel affinity purification and size-exclusion chromatography on a Superose 6 Increase column (GE Healthcare Life Sciences). We biotinylated the protein with BirA ligase as previously described (Clark et al., 2018).

To obtain recombinant S2P for ELISAs, we used Ni Sepharose® Excel (GE Healthcare Life Sciences Cat# 17-3712-02) to purify His₁₄₅-tagged SARS-CoV-2 S2P from the supernatant of Expi293F cells stably expressing this protein (a gift of Bing Chen). We further purified the protein using size exclusion chromatography on a Superpose 6 Increase column.

We synthesized human codon optimized cDNA for antibodies based on publicly available sequences; 4A8 (Chi et al., 2020) (PDB: 7ZCL), B38 (PDB: 7BZS) (Wu et al., 2020), CC12.1 (Yuan et al., 2020a) (PDB: 6XC2), and REGN10933 and REGN10987 (Hansen et al., 2011) (PDB: 7BZ5) (Wu et al., 2020) vector for use in ELISAs, BLI binding studies, and X-ray crystallography. For ELISAs and crystallography the construct includes an N-terminal His₉etag, a TEV protease site and a short linker (aminos acids SGSG). For BLI-binding assays, the construct includes an N-terminal His₉etag, followed by a TEV protease site, a BirA ligase site, and a 7-residue linker (aminos acids GTGSGTG). We produced proteins for ELISAs and BLI-binding assays by using linear polyethylenimine (PEI) MAX (Polysciences Cat# 24765-1) to transfect HEK293T cells grown in suspension and purified by nickel affinity purification. For BLI-binding assays the protein was digested with TEV protease to remove the His₉etag followed by reverse nickel affinity purification. We biotinylated proteins with BirA ligase as previously described (Mahmutovic et al., 2015), followed by a reverse nickel affinity purification step to remove BirA ligase, which contains a His₉etag and cannot be separated by size exclusion chromatography from the SARS-CoV-2 RBD due to its similar size. For crystallography, we produced RBDs by PEI MAX transfection of GnTI⁻/⁻ HEK293S cells grown in suspension or HEK293T cells grown in suspension and also in the presence of kifunensine (Sigma-Aldrich Cat# K1140) at 5 μM, purified these by nickel affinity, and removed the His₉etag by TEV digestion followed by reverse nickel affinity purification. As a final step, we used size exclusion on a Superdex 200 Increase column, in which each recombinant RBD protein ran as a single peak at the expected retention volume.

We subcloned the ectodomain of human ACE2 (GenBank ID: BAB40370.1) residues 18-740, with cDNA obtained as a gift from Michael Farzan, with a C-terminal Fc tag into a pVRC8400 vector containing human IgG1 Fc (a gift from Aaron Schmidt). We expressed the protein in Expili293F™ cells using an ExpiliFectamine™ transfection kit according to the manufacturer’s protocol.
and purified the protein with MabSelect SuRE Resin using the manufacturer’s protocol, followed by size exclusion chromatography on a Superose 6 Increase column, with the protein eluting at the expected retention volume.

**Protein crystallization**

We prepared each Fab:SARS-CoV-2 RBD complex by mixing RBD with 1.5 molar excess of Fab. The mixtures were incubated at 4°C for 1 h prior to purification on a Superdex 200 Increase column in buffer containing 150mM NaCl, 25 mM Tris-HCl, pH 7.5. Each complex co-eluted as a single peak at the expected retention volume. We adjusted the concentration of each complex to 13 mg ml⁻¹ and screened for crystallization conditions in hanging drops containing 0.1 μl of protein and 0.1 μl of mother liquor using a Mosquito protein crystallization robot (SPT Labtech) with commercially available screens (Hampton Research) (see Key resources table). Crystals grew within 24 h for the C1A-B12 Fab:RBD complex in 0.1 M Bispeptide pH 8.5, 20% (w/v) polyethylene glycol 10,000, for the C1A-B3 Fab:RBD complex in 0.2 M Ammonium phosphate dibasic, 20% (w/v) polyethylene glycol 3,350; for the C1A-C2 Fab:RBD complex in 0.03 M citric acid, 0.07M BIS-TRIS propane pH 7.6, 20% (w/v) polyethylene glycol 3,350, and for C1A-F10 Fab:RBD complex in 0.10% (w/v) n-Octyl-B-glucoside, 0.1 M Sodium citrate tribasic dihydrate pH 4.5, and 22% (w/v) polyethylene glycol 3,350.

**Structure determination**

All crystals were flash frozen in mother liquor supplemented with 15% (v/v) glycerol as cryoprotectant. We collected single crystal X-ray diffraction data on Eiger X 16M pixel detectors (Dectris) at a wavelength of 0.979180 Å at the Advanced Photon Source (APS, Argonne, IL) NE-CAT beamline 24-ID-E for the C1A-B12 Fab:RBD and C1A-B3 Fab:RBD complexes and NE-CAT beamline 24-ID-C for the C1A-C2 Fab:RBD and C1A-F10 Fab:RBD complexes. Diffraction data were indexed and integrated using XDS (build 202 00131) (Kabsch, 2010) and merged using AIMLESS (v0.5.32) (Evans and Murshudov, 2013). The structure of the C1A-B12 Fab:RBD complex (space group \( P_2_1_2_1_2_1 \), three copies per ASU) and C1A-F10:RBD complex (space group \( P_2_1_2_1_2_1 \), one copy per ASU) were determined by molecular replacement using Phaser (v2.8.3) (McCoy et al., 2007), with coordinates for the B38 Fab variable domain, constant domain and RBD (PDB ID: 7BZ5) (Wu et al., 2020) used as search models. Three copies were found in the asymmetric unit (ASU). We performed iterative model using O (Jones et al., 1991) and refinement in Phenix (v1.18.2-3874) (Adams et al., 2010) and Buster (v2.10.3) (Bricogne et al., 2017), during which we also built alternative conformations for residue side chains where density was apparent. During refinements, we updated TLS groups calculated using Phenix (Adams et al., 2010) and a python script, as well as occupancy restraints calculated in Buster. During model building, we also customized geometry restraints to prevent large displacement of unambiguous contacts in poor regions; the restraints were released once refinement became stable. Water molecules were automatically picked and updated in Buster, followed by manual examination and adjustment till late-stage refinement. The structures of the C1A-B3:RBD complex (space group \( P_2_1_2_1_2_1 \), three copies per ASU), C1A-C2:RBD complex (space group \( C_2_2_1_1 \), one copy per ASU) and C1A-F10:RBD complex (space group \( C_2_2_1_1 \), one copy per ASU) were determined using RBD and the C1A-B12 Fab variable and constant domains as search ensembles with CDR and flexible loops truncated, with iterative model building and refinement as described above. Data collection, processing and refinement statistics are summarized in Table S2. PDB validation reports are included as Data S1.

**Structural Analysis**

We analyzed the structures and generated figures using PyMOL (Schrödinger).

**Lentivirus pseudotype production**

Human codon optimized SARS-CoV-2 S (GenBank ID: QJR84873.1 residues 1-1246) with a modified cytoplasmic sequence that includes HIV gp41 residues (NRVRQGYS) replacing C-terminal residues 1247-1273 of the S protein (a gift from Nir Hacohen) was subcloned into the pCAGGS expression vector. With this human codon optimized modified S construct as a starting point, we used Gibson assembly to generate the D614GS,D614GS/N439KRBD, D614GS/Q493KRBD,D614GS/Q493RRBD, day 146*, and day 152* S variants. Day 152* S is derived from hCoV-19/USA/MA-JLL-D146/2020 (EPI_ISL_593557) but contains WT sequences at positions 12-18, a deletion spanning NTD residues 142-144, and the additional Y489HRBD mutation (Figure S6). Day 146* S is derived from hCoV-19/USA/MA-JLL-0.5 mM EDTA and spun samples at 10,000 x g for 4 h at 4°C. We removed supernatants and resuspended virus pellets in Opti-MEM (Thermo Fisher Scientific Cat# L30950070) containing 25 mM HEPES and 5% (v/v) FBS and stored these at −80°C.

**Pseudotype neutralization experiments**

We purified polyclonal IgG from human plasma samples using Pierce™ Protein G UltraLink™ Resin (Thermo Fisher Scientific Cat# 53126) following the manufacturer’s protocol. We pre-incubated polyoclnal serum IgG, monoclonal antibodies, or an ACE2-Fc fusion
protein with SARS-CoV-2 S, SARS-CoV-2 S mutants, or VSV G lentivirus pseudotypes in the presence of 0.5 μg ml⁻¹ of polybrene for 1 h at 37°C. Virus antibody mixtures were added to HEK293T-hACE2 with incubation on cells at 37°C for 24 h, and the media replaced with DMEM containing 10% (v/v) FBS, 1% (v/v) penicillin-streptomycin (v/v), and 1 μg ml⁻¹ puromycin. We determined the percent of GFP positive cells by FACS with an iQue Screener PLUS (Intellicyt) 48 h after initial infection. We calculated percent relative entry by using the following equation: Relative entry (%) = (%GFP-positive cells in the presence of antibody/%GFP-positive cells in the absence of antibody) × 100. Antibody neutralization of pseudotypes was calculated as follows: Neutralization (%) = [1−(%GFP-positive cells in the presence of antibody/%GFP-positive cells in the absence of antibody)] × 100.

Live virus PRNT experiments
Monoclonal antibody samples were serially diluted in Dulbecco’s Phosphate-Buffered Saline (DPBS, Thermo Fisher Scientific Cat# 14190144) using half-log dilutions starting at a concentration of 50 μg ml⁻¹. Dilutions were prepared in triplicate for each sample and plated in triplicate. Each dilution was incubated at 37°C for 1 h with 1,000 plaque-forming units ml⁻¹ (PFU ml⁻¹) of SARS-CoV-2 USA-WA1/2020. 200 μl of each dilution was added to the confluent monolayers of NR-596 Vero E6 C1008 cells (ATCC CRL-1586; RRID:CVCL_0574) in triplicate and incubated in a 5% CO₂ incubator at 37°C for 1 h. The cells were rocked gently every 15 min to prevent monolayer drying. Cells were then overlaid with a 1:1 solution of 2.5% (v/v) Avicel RC-591 microcrystalline cellulose and carboxymethylcellulose sodium (DuPont Nutrition & Biosciences) and 2x Modified Eagle Medium (MEM - Temin’s modification, Thermo Fisher Cat# 10370088) supplemented with 100 x antibiotic-antimycotic (Thermo Fisher Scientific Cat# 15240062) and 100 X GlutaMAX both to a final concentration of 2 x, and 10% (v/v) FBS. The plates were then incubated at 37°C for two days. After two days, the monolayers were fixed with 10% (v/v) neutral buffered formalin (NBF) (Fisher Scientific Cat# LC146705) for at least 6 h and stained with 0.2% (v/v) aqueous Gentian Violet (Fisher Scientific Cat# 3233-16) in 10% (v/v) NBF for 30 min, followed by rinsing and plaque counting.

ELISA experiments
We coated NUNC MaxiSorp plates (Thermo Fisher Scientific Cat# 44-2404) with His₆-tagged SARS-CoV-2 S2P, SARS-CoV-2 RBD, or LUJV GP1 (produced as previously described (Mahmutovic et al., 2015)) in PBS overnight at 4°C, followed by a blocking step with PBS containing 3% (v/v) and BSA 0.02% (v/v) Tween. We incubated monoclonal antibodies at a concentration of 100 μg ml⁻¹ for one hour. We then washed samples three times with PBS containing 0.02% (v/v) Tween. We detected bound antibody with horseradish peroxidase (HRP)-coupled anti-human (Fc) antibody (Sigma-Aldrich Cat# A0170).

Biolayer interferometry assays
We performed BLI experiments with an Octet RED96e (Sartorius). For affinity measurements, biotinylated SARS-CoV-2 RBD was loaded onto a streptavidin (SA) sensor (ForteBio) at 1.5 μg ml⁻¹ in kinetic buffer (PBS containing 0.02% Tween and 0.1% BSA) for 100 s. After a baseline measurement for 60 s in kinetic buffer, antibody Fabs were associated for 300 s followed by a 300 s dissociation step. We used ForteBio data analysis software to determine kinetics of binding using a 1:1 binding model. For ACE2-Fc competition experiments, we loaded biotinylated SARS-CoV-2 RBD onto SA sensors (ForteBio) at 1.5 μg ml⁻¹ for 80 s. We associated C1A-B12 Fab or CR3022-Fab at 250 nM or buffer for 180 s followed by an association with ACE2-Fc or CR3022 Fab at a concentration of 250 nM for 180 s.

QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analysis was performed using Prism v8.4.3 (GraphPad Software, https://www.graphpad.com; RRID: SCR_002798). Statistical details for experiments are found in figure legends, including the statistical tests used, the exact value of n, and what n represents.
Supplemental figures

A

B

C

D

E

F

G

(legend on next page)
Figure S1. Isolation of SARS-CoV-2 S-reactive antibodies from a COVID-19 convalescent individual, related to Table 1

(A) Entry levels of SARS-CoV-2 or vesicular stomatitis virus (VSV) lentivirus pseudotypes after pre-incubation with polyclonal immunoglobulins (IgG) purified from the plasma of a COVID-19 convalescent individual (“C1”), a non-immune control donor (“ctrl”), or with an ACE2-Fc fusion protein all at a concentration of 316 μg ml⁻¹. Data are normalized to a no antibody control. Means ± standard deviation from two experiments performed in triplicate (n = 6) are shown. One-way ANOVA with Tukey’s multiple comparisons test. ****p < 0.0001.

(B) Density plot from a FACS experiment to isolate memory B cells that bind phycoerythrin (PE)-labeled streptavidin tetramers coupled to a prefusion-stabilized SARS-CoV-2 S construct (S2P-PE). The approximate location of the sorting gate is shown as a box, and the percentage of cells that fall within the gate is indicated. The left panel is for a control donor and the right panel is for COVID-19 convalescent donor C1. CD19 is a B cell marker.

(C) Whisker plot showing ELISA values for IgG binding to S2P, the SARS-CoV-2 RBD, or a control protein Lujo virus (LUJV) GP1. Antibodies were added at a single concentration of 100 μg ml⁻¹. Dashed line represents the cut off for our definition of antibodies that bind the respective protein.

(D) Antibody heavy and light chain gene usage for SARS-CoV-2 S-reactive monoclonal antibodies. Asterisks indicate clonally related V_H3-53/V_K1-9 antibodies (referred to as “C1A-V_H3-53 antibodies” in the text).

(E-F) Violin plots showing CDR3 loop lengths and somatic hypermutation frequencies (S.H.M.) for S-reactive monoclonal antibodies. The median and quartiles are shown as dashed and dotted lines, respectively. For CDR3 loop lengths, the median and first quartile marker overlap.

(G) SARS-CoV-2 or VSV lentivirus pseudotypes were pre-incubated with 100 μg ml⁻¹ of the indicated monoclonal antibody or an ACE2-Fc fusion protein (indicated in bold) and the mixture was used to infect HEK293T-hACE2 cells. Entry levels were quantified 48 h later using FACS. Data are normalized to a no antibody control. Dashed line indicates 10% relative entry. Means ± standard deviation from two experiments performed in triplicate (n = 6) are shown.
Figure S2. SARS-CoV-2 pseudotype and infectious virus neutralization assays, related to Figure 5 and Table 1

(A) SARS-CoV-2 lentivirus pseudotypes were pre-incubated with monoclonal antibodies at the indicated concentrations and the mixture was used to infect HEK293T-hACE2 cells. Entry levels were quantified 48 h later using FACS. VSV pseudotypes are included as a negative control. Data are normalized to a no antibody control. Means ± standard deviation from two experiments performed in triplicate (n = 6) are shown. For some data points, error bars are smaller than symbols. IC₅₀ values are shown in parentheses.

(B) Infectious SARS-CoV-2 (strain USA-WA1/2020) was incubated with monoclonal antibodies at the indicated concentration with infection of Vero E6 cells subsequently measured in a PRNT assay (Zhang et al., 2020). Means ± standard deviation from three experiments performed in triplicate (n = 9) are shown. Data are normalized to a no antibody control. For some data points, error bars are smaller than symbols. IC₅₀ values are shown in parentheses.

(C) Dose response neutralization assays of C1A-V3-53 and affinity enhanced versions of C1A-B12 with the indicated S pseudotypes. Data are normalized to a no antibody control. Means ± standard deviation from two experiments performed in triplicate (n = 6) are shown. IC₅₀ values are shown in Figures 5A and 5B.

(D) Dose response neutralization assays of REGN10933 and REGN10987 (Baum et al., 2020; Hansen et al., 2020) and CC12.1 (Rogers et al., 2020) with the indicated S pseudotypes. Data are normalized to a no antibody control. Means ± standard deviation from two experiments performed in triplicate (n = 6) are shown. IC₅₀ values are shown in Figure 5C.

(E) Dose response neutralization assays of monoclonal antibody B38 (Wu et al., 2020). Means ± standard deviation from two experiments performed in triplicate (n = 6) are shown. IC₅₀ values are shown in Figure 5C.
Fab affinities for the SARS-CoV-2 RBD were measured using biolayer interferometry. Red lines represent the fit for a 1:1 binding model, and alternate colors represent response curves measured at varying concentrations. Binding kinetics were measured for six concentrations of Fab at twofold dilutions ranging from 500 to 15.6 nM (C1A-B3, C1A-F10, C1A-g1, C1A-g1*), 250 to 7.8 nM (C1A-C2, C1A-H5, C1A-C4), and from 15.6 to 0.49 nM (C1A-B12 and C1A-H6). For affinity enhanced antibodies, binding kinetics were measured at seven concentrations of Fab at twofold dilution ranging from 100 to 1.56 nM (C1A-B12.1) or from 10 to 0.16 nM (C1A-B12.2 and C1A-B12.3). Each experiment was performed at least twice, and representative data are shown.
Figure S4. SARS-CoV-2 receptor-binding domain recognition by C1A-VH3-53 antibodies, related to Figure 1

(A) BLI-based competition assay for C1A-B12 Fab, CR3022 Fab, and human ACE2 ectodomain Fc fusion protein (ACE2-Fc) binding to the SARS-CoV-2 RBD. Arrows show the time point at which the indicated protein was added. Representative results of two replicates for each experiment are shown.

(B) Overlay of ribbon diagrams for X-ray crystal structures of Fab/RBD complexes. CDR loops contacting the RBD are indicated.

(C) Ribbon diagram of the X-ray crystal structure of the RBD bound to the ACE2 ectodomain (PDB ID: 6M0J) (Lan et al., 2020) with the RBD in the same orientation as shown in (B) for comparison.

(D-G) Details of the RBD/antibody interface for C1A-B3. The panels show significant contacts made by antibody CDR loops.
(A) Examples of gene usage and CDR H3 lengths for other VH3-53/3-66 antibodies for which structures are available. All antibodies, which were isolated from COVID-19 convalescent donors, engage the RBD with an essentially identical binding mode. CDR H3 length was determined using IMGT/V-QUEST definitions (Brochet et al., 2008). aa: amino acids. PDB ID: protein data bank identification code.

(B) Structural alignment of variable heavy (HC) and light chain (LC) Fab portions of VH3-53/3-66 antibodies bound to the RBD. Antibodies included in the alignment are listed in (A).

(C-D) Alignment of variable heavy chain (C) and VK1-9-derived light chain (D) gene sequences of VH3-53/3-66-derived antibodies reported here and elsewhere. Antibody sequences were obtained from the RCSB record and protein data bank (PDB) IDs listed in (A). Panels were generated using ESPript3 (Robert and Gouet, 2014) and modified. The Kabat numbering scheme is used.

(legend continued on next page)
(E-F) Interactions occurring at the base of CDR H1 with framework regions are shown for the B38 Fab/RBD complex (PDB: 7BZ5) (Wu et al., 2020) (E) or CV30 Fab/RBD complex (PDB: 6XE1) (Hurlburt et al., 2020) (F). The T28I \( \text{VH} \) mutation adds a hydrophobic contact with G476RBD, and the F27V \( \text{VH} \) mutation probably makes CDR H1 more flexible, allowing local polar contacts to be optimized.

(G) Partial sequence alignment of C1A-VH3-53 and affinity enhanced antibodies C1A-B12.1, C1A-B12.2, and C1A-B12.3.

(H) Infectious SARS-CoV-2 (strain USA-WA1/2020) was incubated with monoclonal antibodies at the indicated concentrations with infection of Vero E6 cells subsequently measured in a PRNT assay. Means ± standard deviation from three experiments performed in triplicate (\( n = 9 \)) are shown. Data are normalized to a no antibody control. For some data points, error bars are smaller than symbols. IC\(_{50}\) values are in parentheses.
Figure S6. Alignment of SARS-CoV-2 S sequences, related to Figure 3

Alignment of SARS-CoV-2 sequences. The following sequences were used for the alignment: Day 18: hCoV-19/USA/MA-JLL-D18/2020 (EPI_ISL_593478); Day 25: hCoV-19/USA/MA-JLL-D25/2020 (EPI_ISL_593479); Day 75: hCoV-19/USA/MA-JLL-D75/2020 (EPI_ISL_593480); Day 81: hCoV-19/USA/MA-JLL-D81/2020 (EPI_ISL_593553); Day 128: hCoV-19/USA/MA-JLL-D128/2020 (EPI_ISL_593554); Day 130: hCoV-19/USA/MA-JLL-D130/2020 (EPI_ISL_593555); Day 143: hCoV-19/USA/MA-JLL-D143/2020 (EPI_ISL_593556); Day 146: hCoV-19/USA/MA-JLL-D146/2020 (EPI_ISL_593557); Day 152: hCoV-19/USA/MA-JLL-D152/2020 (EPI_ISL_593558). Sequences from United Kingdom ("UK") B.1.1.7 hCoV-19/England/20S261299/2020 (EPI_ISL_754289), South Africa ("SA") B.1.351 hCoV-19/South Africa/Tygerberg-461/2020 (EPI_ISL_745186), Brazil ("BR") P.1 hCoV-19/Brazil/AM-20143138FN-R2/2020, United States (USA) B.1.1.7 Q493K hCoV-19/USA/FL-CDC-STM-0000013-F04/2021 (EPI_ISL_884605), UK B.1.1.7 Q493R hCoV-19/England/MILK-11C2FCD/2021 (EPI_ISL_1006449), and USA B1.1.7 Y489H hCoV-19/USA/CA-CDC-STM-A100413/2021 (EPI_ISL_850699) are included for comparison. The “day 146*” sequence shown is a version of the day 146 sequence that retains wild-type residues at positions 12-18, contains an NTD deletion spanning residues 142-144 (instead of 141-143), and contains the Y489H RBD mutation. The “day 152*” sequence shown is a version of the day 152 sequence that contains the Y489H RBD mutation. Both day 146* and day 152* sequences contain mutations in the C-terminal cytoplasmic tail to allow for efficient lentivirus pseudotyping. The figure was generated using ESPriT3 (Robert and Gouet, 2014).
Figure S7. RBD sequence variation in relation to ACE2 interactions and predicted NTD deletion effects, related to Figures 3 and 4

(A) Sequence alignment for S residues spanning the RBD in an immunocompromised individual (Choi et al., 2020) at the indicated time points. RBD residues that interact with ACE2 only, C1A-V3-53 antibodies only, or both, are indicated.

(B) Ribbon diagram of the X-ray crystal structure of an ACE2 ectodomain/RBD complex (PDB ID: 6M0J) (Lan et al., 2020). Residues that are mutated during SARS-CoV-2 persistent infection are shown as dark blue spheres. The K417RBD residue, which is mutated in the B.1.351 and P.1 variants (see Figure 3B), is shown as light blue spheres.

(C-H) Views highlighting where select RBD mutations (see Figures 3D–3I) fall with respect to the ACE2 interface.

(I-J) SARS-CoV-2 day 146* (I) or day 152* (J) S pseudotypes were pre-incubated with an ACE2-Fc fusion protein at the indicated concentrations and the mixture was used to infect HEK293T-hACE2 cells. Entry levels were quantified 48 h later using FACS. Data are normalized to a no antibody control. Means ± standard deviation from two experiments performed in triplicate (n = 6) are shown. IC50 values are shown in parentheses.

(K) Summary of SARS-CoV-2 S N-terminal domain (NTD) deletions occurring during persistent infection of an immunocompromised individual (Choi et al., 2020). Deletions found in United Kingdom (“UK”) B.1.1.7 (hCoV-19/England/202561299/2020, EPI_ISL_754289) and South Africa (“SA”) B.1.351 (hCoV-19/South Africa/Tygerberg-461/2020, EPI_ISL_745186) variants are also included for comparison.

(legend continued on next page)
Residues 141-144, which contain mutations starting on day 75, are shown in dark purple, and residues 242-244, which are mutated in the “SA” B.1.351 SARS-CoV-2 variant (Figure S6), are shown in light purple. The 141-144 deletion would reposition a putative N-linked glycosylation site (N149) and potentially block epitope access.